

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO.	
10/069,228	02/21/2002	Shuji Hinuma	46342/57113 1875	
21874 75	90 09/13/2004		EXAMINER	
EDWARDS &	z ANGELL, LLP	LOCKARD, JON MCCLELLAND		
P.O. BOX 55874 BOSTON, MA 02205			ART UNIT	PAPER NUMBER
			1647	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	on No.	Applicant(s)			
Office Action Summary		10/069,22	28	HINUMA ET AL.			
		Examiner	•	Art Unit			
		Jon M Loc	kard	1647			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
THE I - Externanter - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD F MAILING DATE OF THIS COMMUN nsions of time may be available under the provision SIX (6) MONTHS from the mailing date of this com period for reply specified above is less than thirty (period for reply is specified above, the maximum s re to reply within the set or extended period for repl reply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	IICATION. s of 37 CFR 1.136(a). In no evimunication. 30) days, a reply within the stat statutory period will apply and with will by statute. Cause the apply and with a statute.	ent, however, may a reply be tim utory minimum of thirty (30) day ill expire SIX (6) MONTHS from lication to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status							
1)	Responsive to communication(s) fil	ed on					
2a) <u></u>	This action is FINAL .	2b)⊠ This action is n	on-final.				
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims		•				
5) 6) 7)	Claim(s) <u>1-3</u> is/are pending in the a 4a) Of the above claim(s) is/a Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>1-3</u> are subject to restriction	are withdrawn from co					
Applicati	on Papers						
10)	The specification is objected to by the drawing(s) filed on is/are Applicant may not request that any objected the coath or declaration is objected to	e: a) accepted or b) ection to the drawing(s) b g the correction is requir	oe held in abeyance. See red if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority ι	ınder 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
2) Notice 3) Infor	ce of References Cited (PTO-892) the of Braftsperson's Patent Drawing Review (mation Disclosure Statement(s) (PTO-1449 of the No(s)/Mail Date		4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:				

Art Unit: 1647

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1 and 3, drawn to methods of screening ligands or compounds that promote or inhibit a function of an orphan receptor protein.

Group II, claim(s) 2 (in part), in so far as it is drawn to compounds that promote the function of an orphan receptor protein.

Group III, claim(s) 2 (in part), in so far as it is drawn to compounds that inhibit the function of an orphan receptor protein.

- 2. The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:
- 3. Group I is directed to methods of screening ligands or compounds that promote or inhibit a function of an orphan receptor protein, which is the first method. Groups II-III are drawn to products that are structurally and functionally different from each other and each of which can be made and used without the other. Note that PCT Rule 13 does not provide for multiple products or methods within a single application. Lack of unity is shown because these compounds lack a common utility which is based upon a common structural feature which has been identified as the basis for that common utility.
- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 10/069,228

Art Unit: 1647

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

Page 3

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the

application. Any amendment of inventorship must be accompanied by a request under 37 CFR

1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/069,228

Art Unit: 1647

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jon M. Lockard**, **Ph.D.** whose telephone number is (571) 272-2717. The examiner can normally be reached on Monday through Friday, 8:00 AM to 6:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Brenda Brumback**, **Ph.D.** can be reached on (571) 272-0961.

The fax number for the organization where this application or proceeding is assigned is **703-872-9306**.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Cilian B.O Ware

JML August 24, 2004

EILEEN B. O'HARA PATENT EXAMINER